Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.34 |
| ▸ | FDPS | P14324 | 6/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20975781 | 0.98 | EPHX1 (0.50) | EPHX1TSHRTHRBS1PR2S1PR4 | |
| SCHEMBL22667356 | 0.91 | EPHX1 (0.68) | EPHX1TSHRTHRBS1PR2S1PR4 | |
| SCHEMBL21398350 | 0.91 | EPHX1 (0.61) | EPHX1TSHRTHRBS1PR2S1PR4 | |
| SCHEMBL12825868 | 0.91 | EPHX1 (0.46) | EPHX1TSHRALDH1A1 | |
| SCHEMBL22403813 | 0.88 | EPHX1 (0.56) | EPHX1TSHRTHRBS1PR2S1PR4 | |
| SCHEMBL20644846 | 0.86 | EPHX1 (0.61) | EPHX1TSHRS1PR2S1PR4S1PR1 | |
| SCHEMBL21579003 | 0.86 | EPHX1 (0.61) | EPHX1TSHRS1PR2S1PR4S1PR1 | |
| SCHEMBL22111696 | 0.84 | EPHX1 (0.56) | EPHX1TSHRS1PR2S1PR4S1PR1 | |
| Dimethylamine SCHEMBL7109777 | 0.83 | EPHX1 (0.39) | EPHX1TSHRTHRBALDH1A1GGPS1 | |
| SCHEMBL21549958 | 0.83 | TSHR (0.53) | TSHRTHRBGGPS1FDPSLPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20210355119-A1 | CYANO QUINOLINE AMIDE COMPOUNDS AS HER2 INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2021-11-18 | — | — | US | disclosed |
| WO-2021158840-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | ERBB2, EGFR, ERBB3 | EPHX1 3188/4885TSHR 1566/4885THRB 479/4885 |
| US-20210355119-A1 | CYANO QUINOLINE AMIDE COMPOUNDS AS HER2 INHIBITORS AND METHODS OF USE | ERBB2, EGFR, ERBB3 | EPHX1 3105/4885TSHR 1687/4885THRB 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.